Euthyroidism and Long-Term Remission of Graves' Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report [0.03%]
使用FcRn阻断剂治疗后Graves病甲亢患者的 euthyroidism状态及长期缓解：1例报告
George J Kahaly,Jan Wolf,Maximilian Luffy et al.
George J Kahaly et al.
Background: Neonatal fragment crystallizable receptor (FcRn) blockers selectively inhibit FcRn-mediated IgG recycling, resulting in degradation of IgG autoantibodies, including thyrotropin receptor autoantibodies (TSH-R-A...
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis [0.03%]
分化型甲状腺癌术后碘131清甲治疗不同降TSH目标值的系统评价和 meta 分析
Tatiana Rojas,Paola Solis-Pazmino,Luis A Figueroa et al.
Tatiana Rojas et al.
Background: Preparation for radioiodine (RAI) therapy in differentiated thyroid cancer (DTC) often requires thyroid hormone withdrawal (THW) to achieve thyrotropin (TSH) stimulation. Current guidelines recommend TSH ≥30 ...
Beyond Salt Iodization: Sustained Population Sufficiency and Recurrence of Iodine Deficiency in Pregnant Women in Iran [0.03%]
伊朗孕妇碘缺乏的复发：超越食盐加碘行动，实现持续的人群碘充足
Ladan Mehran,Atieh Amouzegar,Safdar Masoumi et al.
Ladan Mehran et al.
Background: Iodine deficiency disorders (IDDs) remain a public health concern, especially in pregnancy, despite universal salt iodization (USI) programs. Iran has sustained iodine sufficiency since the 1990s through natio...
Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors [0.03%]
基于患者的体外模型揭示了髓样甲状腺癌微环境和对酪氨酸激酶抑制剂耐药性的新见解
Elisa Stellaria Grassi,Viola Ghiandai,Germano Gaudenzi et al.
Elisa Stellaria Grassi et al.
Background: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy with a 10-year mortality rate up to 50%. Current therapies for metastatic MTC comprise various tyrosine-kinase inhibitors, but resistance o...
Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma [0.03%]
家族性非髓样甲状腺癌罕见非编码变异的识别
Daniel F Comiskey Jr,Sandya Liyanarachchi,Joyce Wu et al.
Daniel F Comiskey Jr et al.
Background: Familial nonmedullary thyroid carcinoma (FNMTC) occurs when three or more family members are affected by usually papillary thyroid carcinoma (PTC), the most common form of NMTC. While the heritability to NMTC ...
Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial [0.03%]
安罗替尼联合 sintilimab 治疗BRAF V600E阴性、不可切除或转移性间变性甲状腺癌：一项单中心、单组、II期临床试验
Lin Gui,Haohua Zhu,Le Tang et al.
Lin Gui et al.
Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy. Dabrafenib plus trametinib has shown efficacy in BRAFV600E-mutant ATC, but effective therapies remain limited for patients without...
Liquid Biopsy-Based RET Mutation Profiling to Guide RET Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease [0.03%]
基于液体活检的RET基因突变检测在指导散发性甲状腺髓样癌RET抑制剂治疗中的应用可能适用于肿瘤负荷大及疾病进展期患者
Raffaele Ciampi,Roberta Casalini,Teresa Ramone et al.
Raffaele Ciampi et al.
Background: One of the challenges in tumor molecular profiling for therapeutic decisions is the unavailability of tumor tissue or its inadequacy to provide high-quality nucleic acids. Although tissue biopsy remains the "g...
Yamini Adusumelli,Carter R Petty,Christine E Cherella et al.
Yamini Adusumelli et al.
Background: The risk of hypothyroidism after hemithyroidectomy is not well defined in the pediatric population. We sought to determine the incidence of hypothyroidism after hemithyroidectomy in children and the clinical factors associated w...
ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer [0.03%]
ALK抑制可延长ALK阳性间变性甲状腺癌小鼠模型生存期
Yara Maria Machlah,Tim Brandenburg,Georg Sebastian Hönes et al.
Yara Maria Machlah et al.
Background: Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer with a median survival of less than six months. So far, no therapies offering a survival benefit are established. Thus, new therapeutic approaches are urgentl...